Condition: Advanced Solid Tumor · Sponsor: BioNTech SE
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.
This description comes directly from the study's public registry record.
BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Not Yet Recruiting |
| University of California San Francisco | San Francisco, California, United States | Not Yet Recruiting |
| Hartford Healthcare | Hartford, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Brigitte Harris Cancer Pavilion BHCP | Detroit, Michigan, United States | Recruiting |
| START Midwest, LLC | Grand Rapids, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Hospital | New York, New York, United States | Recruiting |
| Duke Cancer Institute | Durham, North Carolina, United States | Not Yet Recruiting |
+ 55 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07070232